Cytokine receptor agonists can be designed with longer half-lives in circulation and with enhanced penetration of the blood–brain barrier by genetically grafting macrocyclic peptides into the structural loops of fragment crystallizable regions.
- Aphrodite Kapurniotu
- Jürgen Bernhagen
